Featured Papers

  • All
  • MYC
  • Statin

Other Publications

  1. An Actionable Sterol-Regulated Feedback Loop Modulates Statin Sensitivity In Prostate Cancer.
    Joseph Longo, Peter J. Mullen, Rosemary Yu, Jenna E. van Leeuwen, Mehdi Masoomian, Dixon T. S. Woon, Yuzhuo Wang, Eric X. Chen, Robert J. Hamilton, Joan M. Sweet, Theodorus H. van der Kwast, Neil E. Fleshner, Linda Z. Penn.
    Molecular Metabolism. 2019 July; Vol 25, p.119-130.
  2. Modelling the MYC-driven normal-to-tumour switch in breast cancer.
    Lourenco C, Kalkat M, Houlahan KE, De Melo J, Longo J, Done S, Boutros PC, Penn LZ.
    Disease Models & Mechanisms 2019 July; Vol 12(7); dmm038083.

  3. Multiple direct interactions of TBP with the MYC oncoprotein.
    Wei Y, Resetca D, Johansson-Akhe I, Ahlner A, Helander S, Wallenhammar A, Morad V, Raught B, Wallner B, Kokubo T, Tong Y, Penn LZ, Sunnerhagen M.
    Nature Structural & Molecular Biology 2019 November; Vol 26; 1035-1043.
  4. Image-Based Analysis of Protein Stability.
    Hickman KA, Hariharan S, de Melo J, Ylanko J, Lustig LC, Penn LZ, Andrews DW.
    Cytometry Part A 2019 November.

  1. MYC Protein Interactome Profiling Reveals Functionally Distinct Regions that Cooperate to Drive Tumorigenesis.
    Kalkat M, Resetca D, Lourenco C, Chan P-K, Wei Y, Shiah Y-J, Vitkin N, Tong Y, Sunnerhagen M, Done SJ, Boutros PC, Raught B, Penn LZ.
    Molecular Cell. 2018 December; Vol 72, p.1–13.
  2. MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis.
    Tu WB, Shiah Y-J, Lourenco C, Mullen PJ, Dingar D, Redel C, Tamachi A, Ba-Alawi W, Aman A, Al-awar R, Cescon DW, Haibe-Kains B, Arrowsmith CH, Raught B, Boutros PC, Penn LZ.
    Cancer Cell. 2018 October; Vol 34 (4): p.579-595.e8.

  3. MYC dephosphorylation by the PP1/PNUTS phosphatase complex regulates chromatin binding and protein stability.
    Dingar D, Tu WB, Resetca D, Lourenco C, Tamachi A, de Melo J, Houlahan KE, Kalkat M, Chan P-K, Boutros PC, Raught B, Penn LZ.
    Nature Communications. 2018 August; 9(1): p. 3502.

  1. Statin-induced cancer cell death can be mechanistically uncoupled from prenylation of RAS family proteins.
    Yu R, Longo J, van Leeuwen JE, Mullen PJ, Ba-Alawi W, Haibe-Kains B, Penn LZ.
    Cancer Research. 2017 Dec 11. 
  2. Inhibiting MYC binding to the E-Box DNA motif by ME47 decreases tumour xenograft growth.
    Lustig LC, Dingar D, Tu WB, Lourenco C, Kalkat M, Inamoto I, Ponzielli R, Chan WCW, Shin JA, Penn LZ.
    Oncogene. 2017 Dec 7;36(49):6830-6837.
  3. Lysine-52 stabilizes the MYC oncoprotein through an SCFFbxw7-independent mechanism.
    De Melo J, Kim SS, Lourenco C, Penn LZ.
    Oncogene. 2017 Dec 7; 36(49):6815-6822.
  4. MYC deregulation in primary human cancers.
    Kalkat M, De Melo J, Hickman KA, Lourenco C, Redel C, Resetca D, Tamachi A, Tu WB, Penn LZ.
    Genes (Basel). 2017 Jun; 8(6): 151.
  1. The interplay between cell signalling and the mevalonate pathway in cancer.
    Mullen PJ, Yu R, Longo J, Archer MC, Penn LZ.
    Nat Rev Cancer. 2016 Aug 26.
  2. MYC interaction with the tumor suppressive SWI/SNF complex member INI1 regulates transcription and cellular transformation.
    Stojanova A, Tu WB, Ponzielli R, Kotlyar M, Chan PK, Boutros PC, Khosravi F, Jurisica I, Raught B, Penn LZ.
    Cell Cycle. 2016 Jul 2;15(13):1693-705.
  3. ChromNet: Learning the human chromatin network from all ENCODE ChIP-seq data.
    Lundberg SM, Tu WB, Raught B, Penn LZ, Hoffman MM, Lee SI.
    Genome Biol. 2016 Apr 30;17:82.
  1. Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death.
    Pandyra AA, Mullen PJ, Goard CA, Ericson E, Sharma P, Kalkat M, Yu R, Pong JT, Brown KR, Hart T, Gebbia M, Lang KS, Giaever G, Nislow C, Moffat J, Penn LZ.
    Oncotarget. 2015 Sep 29;6(29):26909-21.
  2. Myc and its interactors take shape.
    Tu WB, Helander S, Pilstål R, Hickman KA, Lourenco C, Jurisica I, Raught B, Wallner B, Sunnerhagen M, Penn LZ.
    Biochim Biophys Acta. 2015 May;1849(5):469-83.
  3. BioID identifies novel c-MYC interacting partners in cultured cells and xenograft tumors.
    Dingar D, Kalkat M, Chan PK, Srikumar T, Bailey SD, Tu WB, Coyaud E, Ponzielli R, Kolyar M, Jurisica I, Huang A, Lupien M, Penn LZ, Raught B.
    J Proteomics. 2015 Apr 6;118:95-111.
  4. AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress.
    Sriskanthadevan S, Jeyaraju DV, Chung TE, Prabha S, Xu W, Skrtic M, Jhas B, Hurren R, Gronda M, Wang X, Jitkova Y, Sukhai MA, Lin FH, Maclean N, Laister R, Goard CA, Mullen PJ, Xie S, Penn LZ, Rogers IM, Dick JE, Minden MD, Schimmer AD.
    Blood. 2015 Mar 26;125(13):2120-30.
  5. Integrating RAS status into prognostic signatures for adenocarcinomas of the lung.
    Starmans MH, Pintilie M, Chan-Seng-Yue M, Moon NC, Haider S, Nguyen F, Lau SK, Liu N, Kasprzyk A, Wouters BG, Der SD, Shepherd FA, Jurisica I, Penn LZ, Tsao MS, Lambin P, Boutros PC.
    Clin Cancer Res. 2015 Mar 15;21(6):1477-86.
  1. Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one.
    Pandyra A, Penn LZ.
    Mol Cell Oncol. 2014 Dec 31;1(4):e969133.
  2. Identification of c-MYC SUMOylation by mass spectrometry.
    Kalkat M, Chan PK, Wasylishen AR, Srikumar T, Kim SS, Ponzielli R, Bazett-Jones DP, Raught B, Penn LZ.
    PLoS One. 2014 Dec 18;9(12):e115337.
  3. The role of ligand density and size in mediating quantum dot nuclear transport.
    Tang PS, Sathiamoorthy S, Lustig LC, Ponzielli R, Inamoto I, Penn LZ, Shin JA, Chan WC.
    Small. 2014 Oct 29;10(20):4182-92.
  4. BioID data of c-MYC interacting protein partners in cultured cells and xenograft tumors.
    Chan PK, Srikumar T, Dingar D, Kalkat M, Penn LZ, Raught B.
    Data Brief. 2014 Oct 14;1:76-8.
  5. Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop.
    Pandyra A, Mullen PJ, Kalkat M, Yu R, Pong JT, Li Z, Trudel S, Lang KS, Minden MD, Schimmer AD, Penn LZ.
    Cancer Res. 2014 Sep 1;74(17):4772-82.
  6. MYC activity is negatively regulated by a C-terminal lysine cluster.
    Wasylishen AR, Kalkat M, Kim SS, Pandyra A, Chan PK, Oliveri S, Sedivy E, Konforte D, Bros C, Raught B, Penn LZ.
    Oncogene. 2014 Feb 20;33(8):1066-72.
  7. Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells.
    Goard CA, Chan-Seng-Yue M, Mullen PJ, Quiroga AD, Wasylishen AR, Clendening JW, Sendorek DH, Haider S, Lehner R, Boutros PC, Penn LZ.
    Breast Cancer Res Treat. 2014 Jan;143(2):301-12.
  1. MYC phosphorylation at novel regulatory regions suppresses transforming activity.
    Wasylishen AR, Chan-Seng-Yue M, Bros C, Dingar D, Tu WB, Kalkat M, Chan PK, Mullen PJ, Huang L, Meyer N, Raught B, Boutros PC, Penn LZ.
    Cancer Res. 2013 Nov 1;73(21):6504-15.
  2. Identifying gene locus associations with promyelocytic leukemia nuclear bodies using immuno-TRAP.
    Ching RW, Ahmed K, Boutros PC, Penn LZ, Bazett-Jones DP.
    J Cell Biol. 2013 Apr 15;201(2):325-35.
  3. Involvement of Toso in activation of monocytes, macrophages, and granulocytes.
    Lang KS, Lang PA, Meryk A, Pandyra AA, Boucher LM, Pozdeev VI, Tusche MW, Göthert JR, Haight J, Wakeham A, You-Ten AJ, McIlwain DR, Merches K, Khairnar V, Recher M, Nolan GP, Hitoshi Y, Funkner P, Navarini AA, Verschoor A, Shaabani N, Honke N, Penn LZ, Ohashi PS, Häussinger D, Lee KH, Mak TW.
    Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2593-8.
  4. Identifying Myc interactors.
    Ponzielli R, Tu WB, Jurisica I, Penn LZ.
    Methods Mol Biol. 2013;1012:51-64. doi: 10.1007/978-1-62703-429-6_4.
  1. Targeting tumor cell metabolism with statins.
    Clendening JW, Penn LZ.
    Oncogene. 2012 Nov 29;31(48):4967-78. doi: 10.1038/onc.2012.6.
  2.  Transient structure and dynamics in the disordered c-Myc transactivation domain affect Bin1 binding.
    Andresen C, Helander S, Lemak A, Farès C, Csizmok V, Carlsson J, Penn LZ, Forman-Kay JD, Arrowsmith CH, Lundström P, Sunnerhagen M.
    Nucleic Acids Res. 2012 Jul;40(13):6353-66.
  1. New model systems provide insights into Myc-induced transformation.
    Wasylishen AR, Stojanova A, Oliveri S, Rust AC, Schimmer AD, Penn LZ.
    Oncogene. 2011 Aug 25;30(34):3727-34. doi: 10.1038/onc.2011.88.
  1. Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents.
    Goard CA, Mather RG, Vinepal B, Clendening JW, Martirosyan A, Boutros PC, Sharom FJ, Penn LZ.
    Int J Cancer. 2010 Dec 15;127(12):2936-48.
  2. Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair.
    Luoto KR, Meng AX, Wasylishen AR, Zhao H, Coackley CL, Penn LZ, Bristow RG.
    Cancer Res. 2010 Nov 1;70(21):8748-59.
  3. Dysregulation of the mevalonate pathway promotes transformation.
    Clendening JW, Pandyra A, Boutros PC, El Ghamrasni S, Khosravi F, Trentin GA, Martirosyan A, Hakem A, Hakem R, Jurisica I, Penn LZ.
    Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15051-6.
  4. Characterization of the apoptotic response of human leukemia cells to organosulfur compounds.
    Wong WW, Boutros PC, Wasylishen AR, Guckert KD, O’Brien EM, Griffiths R, Martirosyan AR, Bros C, Jurisica I, Langler RF, Penn LZ.
    BMC Cancer. 2010 Jul 2;10:351.
  5. Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma.
    Clendening JW, Pandyra A, Li Z, Boutros PC, Martirosyan A, Lehner R, Jurisica I, Trudel S, Penn LZ.
    Blood. 2010 Jun 10;115(23):4787-97.
  6. Myc: the beauty and the beast.
    Wasylishen AR, Penn LZ.
    Genes Cancer. 2010 Jun;1(6):532-41.
  7. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance.
    Martirosyan A, Clendening JW, Goard CA, Penn LZ.
    BMC Cancer. 2010 Mar 18;10:103.